Methodological and statistical errors distort the effects of glucagon-like peptide-1 receptor agonist drugs on body composition in patients with type 2 diabetes mellitus

In August of 2025, Wang and colleagues published a systematic review and meta-analysis quantifying the effects of glucagon-like peptide-1 receptor agonist (GLP1RA) drugs on skeletal muscle mass in patients with type 2 diabetes mellitus. This paper is of considerable clinical importance, as sarcopenia, obesity, and diabetes are prevalent conditions of high public health interest. Despite the clinical importance of this meta-analysis, its effect estimates and conclusions are distorted by several common meta-analytic errors. A preliminary check of the article revealed errors across several steps of the meta-analytic process. The present correspondence identifies and describes specific errors related to study inclusion, risk of bias assessment, data extraction, analysis, and interpretation. In some instances, errors were severe enough to flip the conclusions derived from statistical tests. The present correspondence does not purport to identify every error in the meta-analysis by Wang and colleagues, but presents objective evidence to raise concerns that warrant clarification and correction.